May 24, 2016 7:32am
AST-OPC1 was successful in all five patients with no serious adverse events associated with the administration of the cells, with AST-OPC1 itself, or with the immunosuppressive regimen.
May 24, 2016 7:32am
AST-OPC1 was successful in all five patients with no serious adverse events associated with the administration of the cells, with AST-OPC1 itself, or with the immunosuppressive regimen.
35 companies, 1 interpreter!
Insight, foresight and recommendation
6 hours 46 min ago
RegMed Investors (RMi) Closing Bell: welcoming the upside trend
15 hours 45 min ago
RegMed Investors’ (RMi) pre-open: finding our way
My motto … never leave an investor uninformed! I say today what others won’t, so you can do what others can’t.
My name is Henry McCusker; I endorse these opinions under my own name and with a subscription based membership.
Do you have an opinion you would like to share with us? We would like to hear from you.
Please e-mail us at hwm@regmedinvestors.com.
Editor and Publisher ... Henry McCusker enters his tenth (10th) year at RegMed Investors